ArticleAmerican journal of translational research2021
Deanxit can improve the dizziness, anxiety, and quality of life of patients with chronic subjective dizziness.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain-bladder axis.Scientific reports · 2025Trial
- Case report: Extrapontine myelinolysis combined with flupentixol- and melitracen-induced dysphagia.Frontiers in pharmacology · 2023Article
- Correlation Between Refractory Laryngopharyngeal Reflux Disease and Symptoms of Anxiety and Depression.Neuropsychiatric disease and treatment · 2022Article
- Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial.Frontiers in medicine · 2022Article
- Short-course antidepressant therapy reduces discontinuation syndrome while maintaining treatment efficacy in patients with refractory functional dyspepsia: A randomized controlled trial.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was designed to analyze the clinical effectiveness of Deanxit (DEA) for treating chronic subjective dizziness (CSD).
methodsA total of 110 CSD patients (all from a community survey) admitted to our hospital from August 2018 to August 2020 were recruited as the study cohort. Among them, 60 who underwent DEA treatment were placed in the research group (RG) and 50 who underwent basic treatment were placed in the control group (CG). The two groups' efficacy, their dizziness disability rating scale (DHI) scores, the improvement in their clinical symptoms (duration of dizziness, frequency of dizziness attacks), their anxiety and depression (i.e., their Hamilton Anxiety Scale (HAMA) scores) and their Hamilton Depression Scale (HAMD)) scores, their sleep quality and their quality of life (short form 36 (SF-36) health survey scores) were observed and compared.
resultsCompared with the CG, the DHI scores, the dizziness durations, the number of dizziness attacks and the HAMA and HAMD scores in the RG were markedly lower than they were in the CG, and the sleep quality levels and SF-36 scores were higher than they were in the CG.
conclusionDEA treatment helps to improve the dizziness, anxiety, and quality of life of CSD patients.
Indexed as
Identifiers
34540052PMC8430134W3200873884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.